| 词条 | Indatuximab ravtansine |
| 释义 |
| Verifiedfields = changed | verifiedrevid = 458273659 | type = mab | image = | alt = | mab_type = mab | source = xi/o | target = SDC1 | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} | ChemSpiderID = none | CAS_number_Ref = {{cascite|changed|??}} | CAS_number = 1238517-16-2 | ATC_prefix = none | ATC_suffix = | PubChem = | DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank = | chemical_formula = | molecular_weight = }} Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate. It is the anti-CD138 chimerized MAb (nBT062)[1] linked to the maytansinoid DM4.[1] It is being investigated as part of a treatment for multiple myeloma.[1] Clinical trialsMultiple MyelomaPreliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.[1] Follow up data reported "encouraging efficacy" in Dec 2014.[2] Other{{as of|December 2014}} it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.[2]Mechanism of actionCD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells.[1] The antibody part binds to CD138 on the target cells and then the DM4 kills the cell. See also
References1. ^1 2 3 4 Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients {{monoclonals for tumors}}{{monoclonal-antibody-stub}}{{antineoplastic-drug-stub}}2. ^1 Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone 2 : Monoclonal antibodies|Experimental drugs |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。